Philip Morris International
PM
$190.82
-0.61%
Philip Morris International Inc. is a global tobacco company that sells cigarettes and reduced-risk products, including heated tobacco, vapes, and oral nicotine offerings, primarily outside the United States. It is a dominant player in the industry, with its IQOS brand leading the heated tobacco segment and Zyn dominating nicotine pouches in most markets. The current investor narrative centers on the company's successful transition to smoke-free products, with strong growth in IQOS and Zyn driving revenue acceleration and margin expansion, while regulatory and competitive dynamics remain key debates.…
PM
Philip Morris International
$190.82
Related headlines
Investment Opinion: Should I buy PM Today?
Rating: Hold. PM is a high-quality defensive growth stock with strong smoke-free momentum, but its premium valuation and near-term upside limited to 3.9% (average analyst target $200.53) suggest a balanced risk/reward. The thesis is that RRP growth will sustain double-digit revenue increases and margin expansion, justifying the premium multiple.
Supporting Evidence: Revenue grew 9.09% YoY in Q1 2026, accelerating from 6.5% in Q4 2025. Operating margin improved to 38.37% from 32.55% sequentially. Free cash flow TTM of $10.7 billion yields 4.3%. The forward P/E of 21.12x is below the 5-year high of 29.3x, suggesting room for multiple expansion if growth accelerates. However, the PEG ratio of 0.36 indicates the stock is undervalued relative to its earnings growth rate, supporting the Hold rating.
Risks & Conditions: The Hold would upgrade to Buy if RRP revenue growth exceeds 15% for two consecutive quarters or if the P/E compresses below 18x. It would downgrade to Sell if RRP growth decelerates below 5% or if regulatory actions materially impact Zyn or IQOS. Overall, PM is fairly valued relative to its growth prospects, trading at a premium to peers but with a PEG below 1.0, suggesting it is not overvalued.
Sign up to view all
PM 12-Month Price Forecast
PM's fundamentals are strong, with accelerating revenue, expanding margins, and robust cash flow. The stock's premium valuation is justified by its growth trajectory in smoke-free products, which are gaining traction globally. However, regulatory risks and the stock's proximity to its 52-week high limit upside potential in the near term. The base case of steady growth to $200 is most likely, but a bullish scenario could materialize if RRP adoption accelerates. The stance is bullish with medium confidence, as the risk/reward is balanced but tilted positive given the PEG ratio below 1.0.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $203.80 and implied upside of +6.8% versus the current price.
Average Target
$203.80
0 analysts
Implied Upside
+6.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $225
Analyst target range
The stock is covered by 15 analysts, with a consensus recommendation of 'Buy' and an average target price of $200.53, implying approximately 3.9% upside from the current price of $193. The distribution leans bullish, with a mean recommendation score of 1.81 (where 1 is strong buy and 5 is sell). The target range spans from a low of $171 to a high of $221, representing a 29% spread between the low and high. The high target of $221 assumes continued strong growth in IQOS and Zyn, while the low target of $171 prices in potential regulatory headwinds or slower adoption. Recent ratings from UBS (Neutral), Morgan Stanley (Overweight), and Needham (Buy) indicate a generally positive but cautious sentiment, with a wide target spread reflecting uncertainty about the pace of smoke-free transition.
Drowning in data?
Find the real signal!
Bulls vs Bears: PM Investment Factors
PM presents a compelling growth story driven by its successful transition to smoke-free products, with IQOS and Zyn leading their categories. Revenue accelerated to 9.09% YoY in Q1 2026, margins are expanding, and free cash flow is robust. However, the stock trades at a premium valuation (22x P/E vs 15x industry) and faces regulatory risks that could slow adoption. The bull case rests on continued RRP momentum and margin expansion, while the bear case centers on valuation compression and regulatory setbacks. The single most important tension is whether smoke-free growth can sustain double-digit rates to justify the premium multiple; if growth decelerates, the stock could re-rate lower.
Bullish
- Strong Smoke-Free Growth: Reduced-risk products (RRPs) contributed $4.379 billion in Q1 2026, driving 9.09% YoY revenue growth. IQOS and Zyn are market leaders in heated tobacco and nicotine pouches, respectively, positioning PM for continued share gains in the growing smoke-free category.
- Expanding Margins: Operating margin improved to 38.37% in Q1 2026 from 32.55% in Q4 2025, a 582 bps sequential expansion. This reflects operating leverage from higher RRP volumes and cost efficiencies, supporting earnings growth.
- Strong Free Cash Flow: Free cash flow TTM is $10.666 billion, yielding ~4.3% of market cap. This robust cash generation supports a 3.46% dividend yield and aggressive share buybacks, which have contributed to negative equity but enhanced EPS.
- Analyst Consensus Buy: 15 analysts rate PM a Buy with an average target of $200.53, implying 3.9% upside. The high target of $221 suggests potential for 14.5% upside if smoke-free adoption accelerates.
Bearish
- Premium Valuation vs Peers: Trailing P/E of 22.06x is a 47% premium to the industry average of 15x. While justified by growth, any slowdown in RRP adoption could lead to multiple compression, especially if interest rates remain elevated.
- Regulatory Headwinds: Global tobacco regulation is tightening, with potential flavor bans, marketing restrictions, and excise tax increases on nicotine products. The FDA's stance on Zyn in the US and EU's tobacco directive revisions pose risks to volume growth.
- Negative Equity Concerns: Debt-to-equity of -4.89 reflects negative shareholders' equity due to extensive share buybacks. While cash flow covers debt, this financial structure increases leverage risk if earnings decline.
- Combustible Revenue Decline: Combustible product revenue of $5.767 billion in Q1 2026 is still the majority of sales, and cigarette volumes are declining globally. Any acceleration in volume decline could pressure overall revenue growth.
PM Technical Analysis
The stock is in a sustained uptrend, with a 1-year price change of +19.8% and currently trading at $193, which is 96.6% of its 52-week range (high $199.78, low $142.11). This positioning near the highs suggests strong momentum but also potential overextension, as the stock has rallied significantly from its 52-week low. Short-term momentum is accelerating, with 1-month and 3-month price changes of +7.95% and +17.54%, respectively, both outpacing the 1-year trend. The 1-month change of +7.95% versus the 1-year change of +19.8% indicates that recent momentum is stronger than the longer-term average, suggesting a potential trend acceleration rather than a divergence. The stock's beta of 0.405 indicates it is significantly less volatile than the market, which is typical for a defensive consumer staple. Key support is at the 52-week low of $142.11, while resistance is at the 52-week high of $199.78. A breakout above $199.78 would signal a continuation of the uptrend, while a breakdown below $142.11 would be a bearish reversal.
Beta
0.41
0.41x market volatility
Max Drawdown
-21.3%
Largest decline past year
52-Week Range
$142-$208
Price range past year
Annual Return
+16.3%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +7.4% | +0.2% |
| 3m | +14.7% | +3.7% |
| 6m | +6.3% | +8.0% |
| 1y | +16.3% | +18.2% |
| ytd | +19.0% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
Revenue is growing, with the most recent quarterly revenue of $10.146 billion (Q1 2026) up 9.09% year-over-year, accelerating from the 6.5% growth in Q4 2025. The growth is driven by reduced-risk products, which contributed $4.379 billion in the quarter, while combustible products contributed $5.767 billion. The company is highly profitable, with net income of $2.438 billion in Q1 2026 and a gross margin of 68.06%, which has been stable around 67-68% over recent quarters. Operating margin improved to 38.37% in Q1 2026 from 32.55% in Q4 2025, indicating expanding profitability. The balance sheet shows a debt-to-equity ratio of -4.89 (negative equity due to large share buybacks), but free cash flow TTM is strong at $10.666 billion, providing ample liquidity. The current ratio of 0.96 is slightly below 1, but the company generates sufficient cash to cover obligations, with a free cash flow yield of approximately 4.3% based on market cap.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 22.06x, while the forward P/E is 21.12x, implying the market expects earnings growth of about 4.5% over the next year. The stock trades at a premium to the industry average P/E of 15x (estimated from consumer defensive tobacco peers), a 47% premium. This premium is justified by superior growth in reduced-risk products and higher margins. Historically, the stock's trailing P/E of 22.06x is near the middle of its 5-year range (15x to 29x), suggesting it is not overvalued relative to its own history. The current P/E is below the 5-year high of 29.3x, indicating room for multiple expansion if growth accelerates.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: PM's negative equity of -4.89 debt-to-equity signals aggressive leverage from share buybacks, though free cash flow of $10.7 billion TTM provides ample coverage. The current ratio of 0.96 indicates slightly tight liquidity, but strong operating cash flow mitigates near-term concerns. Revenue concentration in combustible products (57% of Q1 2026 sales) remains a risk as cigarette volumes decline globally; any acceleration in decline could pressure earnings. The payout ratio of 76% is high, limiting dividend growth potential if earnings falter.
Market & Competitive Risks: The stock's beta of 0.405 suggests low market correlation, but its premium P/E of 22x versus the industry average of 15x makes it vulnerable to multiple compression if growth disappoints. Regulatory risks include potential FDA restrictions on Zyn in the US and EU flavor bans for heated tobacco. Competition from British American Tobacco's glo and Japan Tobacco's Ploom could erode IQOS market share. The wide analyst target spread ($171-$221) reflects uncertainty about the pace of smoke-free adoption.
Worst-Case Scenario: A combination of regulatory setbacks (e.g., Zyn ban in key markets), slower RRP adoption, and a recession pressuring cigarette volumes could drive the stock to its 52-week low of $142.11, a 26.4% decline from the current price of $193. This scenario would likely involve multiple compression to 16x P/E, in line with the industry average, and earnings downgrades. The maximum drawdown of -21.96% historically suggests such a decline is plausible but not the base case.
FAQ
The key risks are: 1) Regulatory risk: Flavor bans or marketing restrictions on IQOS and Zyn in major markets like the EU and US could slow RRP adoption. 2) Valuation risk: The premium P/E of 22x leaves the stock vulnerable to multiple compression if growth disappoints. 3) Combustible decline: Cigarette volumes are declining globally, and if RRP growth fails to offset, overall revenue could stagnate. 4) Financial leverage: Negative equity from buybacks increases financial risk, though free cash flow of $10.7 billion provides a cushion. The most severe risk is a regulatory shock that could drive the stock to the 52-week low of $142.11, a 26.4% decline.
The 12-month forecast is based on three scenarios: Bull case (25% probability) targets $200-$221, driven by accelerated RRP adoption and margin expansion. Base case (55% probability) targets $185-$200, assuming steady 9% RRP growth and stable margins. Bear case (20% probability) targets $171-$185, reflecting regulatory headwinds and slower growth. The base case is most likely, with the stock trading near the average analyst target of $200.53. Key assumptions include continued IQOS/Zyn momentum and no major regulatory setbacks. The AI assessment is bullish with medium confidence, citing strong fundamentals but limited near-term upside.
PM's trailing P/E of 22.06x is a 47% premium to the industry average of 15x, suggesting it is overvalued relative to peers. However, the forward P/E of 21.12x is below the 5-year high of 29.3x, and the PEG ratio of 0.36 indicates it is undervalued relative to its earnings growth rate. The market is pricing in continued strong growth in reduced-risk products, which is justified by the company's leadership in IQOS and Zyn. Compared to its own history, the current P/E is near the middle of the 5-year range (15x-29x), implying fair valuation. The premium to peers is warranted by superior growth and margins, but any slowdown could lead to multiple compression.
PM is a good buy for long-term investors seeking a defensive growth stock with a 3.46% dividend yield. The company's smoke-free products (IQOS, Zyn) are driving 9.09% revenue growth, and operating margins are expanding to 38.37%. However, the stock trades at a premium P/E of 22x versus the industry average of 15x, and the average analyst target of $200.53 implies only 3.9% upside. For growth-oriented investors with a 3-5 year horizon, the PEG ratio of 0.36 suggests undervaluation relative to earnings growth. For short-term traders, the limited upside and regulatory risks make it less attractive. Overall, it is a buy on dips, especially if the P/E compresses below 18x.
PM is best suited for long-term investment (3-5 years) due to its defensive nature (beta 0.405), growing dividend (3.46% yield), and structural growth in smoke-free products. Short-term trading is less attractive because the stock is near its 52-week high and has limited upside to the average analyst target. The low volatility and steady earnings growth make it a core holding for income-oriented portfolios. A minimum holding period of 3 years is recommended to benefit from the smoke-free transition and dividend compounding. Short-term catalysts like earnings beats could provide trading opportunities, but the risk/reward is better for long-term investors.
